News
Agent reduces fibrosis, improves platelet counts in MF
VIENNA—The immunotherapeutic agent PRM-151, when given alone or in combination with ruxolitinib, can reduce bone marrow fibrosis and improve...
News
Inactivating an enzyme can eradicate T-ALL
Preclinical research suggests that inactivating a single enzyme could eradicate or prevent T-cell acute lymphoblastic leukemia (T-ALL). The...
News
CT after unexplained VTE unnecessary, study suggests
Photo by Angela Mary Butler TORONTO—A CT scan of the abdomen and pelvis does not improve cancer detection in people with unexplained venous...
News
Targeted agent shows early promise for NHL
follicular lymphoma LUGANO—An anti-CD37 antibody-radionuclide conjugate provides sustained efficacy and a manageable safety profile in patients...
News
Drug reverses anticoagulant effect of dabigatran
dabigatran in real-world situations. In the RE-VERSE AD trial, idarucizumab normalized diluted thrombin time (dTT) and ecarin clotting time (ECT...
News
FDA grants vaccine orphan designation for MM
The US Food and Drug Administration (FDA) has granted a novel vaccine orphan designation as a treatment for multiple myeloma (MM). The vaccine,...
News
Bridge therapy not necessary in AFib, team says
TORONTO—Bridge anticoagulant therapy appears to be unnecessary in patients with atrial fibrillation (AFib) undergoing elective surgery, according...
News
FDA approves antiplatelet drug for PCI patients
Photo courtesy of The Medicines Company The US Food and Drug Administration (FDA) has approved the intravenous antiplatelet agent cangrelor (...
News
Combo shows promise for heavily pretreated MM
Image by Louis Heiser and Robert Ackland VIENNA—Combining a novel agent with dexamethasone can produce successful results where other treatments...
News
EZH2 inhibitor proves active in rel/ref NHL
LUGANO—The EZH2 inhibitor tazemetostat (EPZ-6438) has shown “meaningful clinical activity” as monotherapy in patients with advanced non-Hodgkin...
News
New insight into blood production
in the bone marrow Scientists say they have identified a family of multipotent progenitor (MPP) cells that are the first to arise from...
News
Jury still out on combo for elderly AML
Photo courtesy of NIH VIENNA—A 2-drug combination can produce complete responses (CRs) in elderly patients with newly diagnosed acute myeloid...
News
SVT may indicate undiagnosed cancers
Image by Andre E.X.
News
Combo delays progression in relapsed CLL
VIENNA—Results of the COMPLEMENT 2 trial indicate that adding ofatumumab to treatment with fludarabine and cyclophosphamide (OFC) can improve some...
News
Triplet can provide clinical benefit in rel/ref MM
VIENNA—Combination therapy consisting of the HDAC6 inhibitor ricolinostat, pomalidomide, and dexamethasone can provide a clinical benefit for...